Predictors of heart failure development in type 2 diabetes: a practical approach.


Journal

Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087

Informations de publication

Date de publication:
09 2019
Historique:
pubmed: 21 6 2019
medline: 4 4 2020
entrez: 21 6 2019
Statut: ppublish

Résumé

Although type 2 diabetes (T2D) is one of the most important risk factors that leads to the development of de novo heart failure, there are limited data, particularly from a practical/qualitative standpoint, about predictors of heart failure in this population. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been shown to prevent the development of heart failure and the composite of heart failure and cardiovascular death in patients with T2D without known heart failure who have either established atherosclerotic vascular disease or multiple risk factors. The concept of primary prevention of heart failure has led many clinicians to inquire if there are specific risk/enrichment factors that may predict an increased risk of heart failure. In this review, we identify some general and diabetes-specific risk factors that are associated with an increased risk of developing heart failure in people with T2D.

Identifiants

pubmed: 31219877
doi: 10.1097/HCO.0000000000000647
pmc: PMC6727884
doi:

Substances chimiques

Hypoglycemic Agents 0
Sodium-Glucose Transporter 2 Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

578-583

Subventions

Organisme : NIGMS NIH HHS
ID : U54 GM115428
Pays : United States

Références

JAMA. 2001 Jul 25;286(4):421-6
pubmed: 11466120
Med Clin North Am. 2012 Jan;96(1):87-91
pubmed: 22391253
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
JACC Basic Transl Sci. 2018 Jun 25;3(3):415-419
pubmed: 30062227
Lancet Diabetes Endocrinol. 2016 Oct;4(10):840-9
pubmed: 27599814
N Engl J Med. 2013 Oct 3;369(14):1327-35
pubmed: 23992602
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Diabetes Care. 2004 Mar;27(3):704-8
pubmed: 14988289
Lancet Diabetes Endocrinol. 2016 Apr;4(4):294-6
pubmed: 27016320
Lancet. 2015 May 23;385(9982):2067-76
pubmed: 25765696
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Circulation. 2015 Sep 8;132(10):923-31
pubmed: 26152709
JACC Heart Fail. 2015 Feb;3(2):136-45
pubmed: 25660838
JACC Heart Fail. 2018 Oct;6(10):813-822
pubmed: 30098964
Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):51-7
pubmed: 15386819
Eur J Heart Fail. 2014 Nov;16(11):1153-6
pubmed: 25315254
JACC Heart Fail. 2017 Aug;5(8):552-560
pubmed: 28624486
Lancet. 2007 Sep 29;370(9593):1129-36
pubmed: 17905165
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Circulation. 2014 Oct 28;130(18):1579-88
pubmed: 25189213
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
JACC Heart Fail. 2017 Aug;5(8):543-551
pubmed: 28711447
Lancet. 2019 Jan 5;393(10166):3-5
pubmed: 30424891
JACC Heart Fail. 2018 Jun;6(6):445-451
pubmed: 29525332
Circulation. 2018 Jan 9;137(2):119-129
pubmed: 28904068
Diabetologia. 2018 Oct;61(10):2108-2117
pubmed: 30132036
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Can J Cardiol. 2017 Nov;33(11):1342-1433
pubmed: 29111106
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
J Am Coll Cardiol. 2018 Dec 18;72(24):3200-3223
pubmed: 30497881
Circulation. 2013 Oct 15;128(16):e240-327
pubmed: 23741058
J Am Coll Cardiol. 2013 Oct 8;62(15):1365-72
pubmed: 23810874
Circulation. 2019 Mar 12;139(11):1458-1460
pubmed: 30855996
Eur J Heart Fail. 2018 May;20(5):853-872
pubmed: 29520964
Circulation. 2010 Jul 27;122(4):352-60
pubmed: 20625114
Circulation. 2019 Jan 15;139(3):351-361
pubmed: 30586723
N Engl J Med. 2002 Aug 1;347(5):305-13
pubmed: 12151467
J Am Heart Assoc. 2018 May 16;7(11):
pubmed: 29769203
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
JAMA Cardiol. 2016 May 1;1(2):126-35
pubmed: 27437883
N Engl J Med. 2018 Aug 16;379(7):633-644
pubmed: 30110583
Diabetes Care. 2017 Dec;40(12):1763-1770
pubmed: 28986504
BMJ. 2016 Jul 12;354:i3477
pubmed: 27413012
Lancet Diabetes Endocrinol. 2014 Oct;2(10):843-51
pubmed: 24731668
Circulation. 2018 Oct 9;138(15):1537-1550
pubmed: 29941478
J Am Coll Cardiol. 2019 Jun 4;73(21):2780-2782
pubmed: 30885684

Auteurs

Subodh Verma (S)

Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario.

Abhinav Sharma (A)

McGill University Health Centre, Montreal, Quebec, Canada.

Naresh Kanumilli (N)

Northenden Group Practice, Manchester, UK.

Javed Butler (J)

University of Mississippi Medical Center, Jackson, Mississippi, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH